Table 3.

Clinical characteristics, laboratory results and imaging findings of patients with SARS-CoV-2 vaccine-induced chronic autoimmune thyroiditis

N°	Author (Ref)	Gender	Age	Type of vaccine	Dose	Time (days)	Neck pain	TSH	FT4	TPO-Ab	Tg-Ab	ESR	CRP	Thyroid ultrasound, Colour flow Doppler	Thyroid scintigraphy	Treatment	Follow-up
1	Leber [36]	F	32	Inactivated	2nd	1	Y	13.2	Normal	Y	Y					Methylprednisolone for 5 days	Normal TSH after corticosteroid treatment
2	Lee [15]	M	33	Inactivated	1st	10	N	0.012	37.4	N	Y	37	5.16	Heterogenous echogenicity, decreased vascularity	Low thyroid scan uptake
3	Pujol [17]	M	32	mRNA	1st	10	NA	0.01	30.5	Y	Y	NA	NA	Inflammatory process	Absence of uptake	No treatment	At 8 weeks: TSH = 116 mU/L Levothyroxine treatment
4	Siolos [16]	F	39	Adenovirus vectored	1st	21	N	<0.03	20.47	Y	Y	17	1		Markedly decreased thyroid uptake	No treatment	Euthyroid state at 8 weeks
5	Capezzone [37]	M	34	mRNA	1st	7	N	0.01	24	N	N	5	<0.6	Normal volume, mild hypoechogenicity, diffuse heterogenous echotexture, decreased blood flow	Decreased thyroid uptake	No treatment	Normal TSH after 4 weeks
6	Capezzone [37]	F	29	mRNA	1st	7	N	0.003	21.7	N	N	10	<0.6	Normal volume, mild hypoechogenicity, diffuse heterogenous echotexture, decreased blood flow	Decreased thyroid uptake	No treatment	Normal TSH after 4 weeks

Age in years, Time in days, TSH in mU/L, and FT4 in pmol/l

Gender F female, M male, Y yes, N not present, ESR Erythrocyte sedimentation rate (mm/h), CRP C-reactive protein (mg/l), TPO-Ab TPO antibody, Tg-Ab Tg antibody, NA not available